TheraCell Announces The First Surgical Uses Of Its Novel TheraFuze DBF® Fiber Bag™ For Graft Containment In Spinal Surgery
TheraCell completes first two surgical cases with its unique graft containment product, the world s first biologic bag - The Bag That Is A Graft™
News provided by
Share this article
Share this article
LOS ANGELES, April 6, 2021 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that it has completed the first two spine surgical cases using the TheraFuze DBF® Fiber Bag™. The Fiber Bag is an allograft alternative to the resorbable polymer mesh bag products that are currently on the market. It is made from 100% demineralized cortical bone fibers generated with the company s patented manufacturing process and formed using its proprietary FiberLok™ technology. This allows the Fiber Bag to maintain its form and integrity after filling and rehydration, permitting manipulation and implantation by the surgeon.
TheraCell Announces Immediate Release Of Its TheraFuze DBF® Fiber Bag Solution For Graft Containment In Spinal Surgery
TheraCell s DBF Fiber Bag™ - The Bag That Is A Graft™
News provided by
Share this article
Share this article
LOS ANGELES, March 2, 2021 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that its newest procedure-specific fiber graft form, the TheraFuze DBF Fiber Bag, is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures. Additionally, the company announced that a patent (U.S. Patent Number 10,639,157) related to the Fiber Bag was issued by the United States Patent and Trademark Office in May 2020.
TheraCell Announces Immediate Release Of Its TheraFuze DBF® Fiber Bag Solution For Graft Containment In Spinal Surgery prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
TheraCell Announces First Surgical Use Of TheraFuze DBF® Fiber Bullets™ In An Interbody TLIF Cage
TheraCell completes first surgical case with the TheraFuze DBF® Fiber Bullets™ offering surgeons an improved solution for allograft delivery in MIS surgeries
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 30, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that it has completed the first surgical case using its TheraFuze DBF® Fiber Bullets™. This unique DBF fiber form is designed for minimal access delivery into expandable cages, revisions and other surgical applications.
The lyophilized Fiber Bullets™ can be dispensed using minimally invasive techniques into the desired site, delivering osteoconductive demineralized bone fibers with osteoinductive potential to stimulate new bone formation for long term structural stability.
TheraCell Announces Delivery Of Over 25,000 Of Its Licensed Bone Fiber Grafts
Products Have Reached an Annual End Customer Sales Rate Approaching $30M
News provided by
Share this article
Share this article
LOS ANGELES, Dec. 17, 2020 /PRNewswire/ TheraCell Inc., a leading allograft solution company, today announced that over 25,000 of its licensed demineralized bone fiber products have been delivered by its licensee partners. TheraCell s partners have seen steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30M.
(PRNewsfoto/TheraCell, Inc.)
TheraCell has licensed the base fiber technology to AlloSource to produce and market AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, and to produce private label products to be marketed by other orthopedic companies. The technology has also been licensed to Australian Biotechnologies to produce and market AlloVance® Xpress Fibres, AlloVance® Xpress Hybrid, AlloVance®